Eli Lilly’s
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
Eli Lilly 's expanding obesity drug pipeline is giving us little reason to take profits at this point — even after a massive run to record highs. "It's a parabolic spike. I don't buy parabolas," Jim Cramer said on " Squawk on the Street " on Monday.
Eli Lilly to Buy 3 Vaccine Developers
Eli Lilly has a long history in infectious diseases.
Eli Lilly to Buy 3 Vaccine Developers
Eli Lilly has a long history in infectious diseases.
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Jacob Van Naarden is busy. In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development. And Lilly, now the world's largest pharmaceutical company, is hungrier than ever for deals.
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.
US pharma giant is unhappy with Germany; CEO calls planned healthcare reform ‘terrible’
US pharmaceutical giant Eli Lilly has announced that it is halving its massive €2.3 billion ($2.67 billion) investment plan to build a high-tech manufacturing plant in Alzey, Rhineland-Palatinate in what can be seen a major blow to Germany’s industrial ambitions. The rollback targets a facility originally designed to be one of Eli Lilly’s largest and most modern factories worldwide, intended to produce its highly sought-after weight-loss and diabetes injection, Mounjaro. Eli Lilly CEO Dave...
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly...
AstraZeneca advances weight-loss pill to take aim at obesity leaders
Pill from drugmaker would put it into competition with market leaders Novo Nordisk and Eli Lilly
The Wegovy pill is still dominating the GLP-1 pill market
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly’s GLP-1 pill.